When the company in the United States first became aware of the problem—what became an emerging crisis of abuse—we met with the FDA frequently to share knowledge and to discuss plans to address the condition. We did put out at the time, although it was prior to my involvement, a multi-point plan that involved both the drug development activities that would ultimately produce the OxyNEO product nine years later, but also other risk mitigation activities that focused on education, proper prescribing, safe use, storage, and disposal initiatives, tamper-resistant prescription pads—we've heard other witnesses describe the benefit from these—law enforcement, and education. It was a multi-part plan.
I think most important to this discussion here in Canada is that we worked very closely hand in hand with the regulators and external experts in the United States to get to where we are today.